Diffuse large B-cell lymphoma
LH Sehn, G Salles - New England Journal of Medicine, 2021 - Mass Medical Soc
Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …
2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management
S Susanibar‐Adaniya, SK Barta - American journal of …, 2021 - Wiley Online Library
Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
L Meriranta, A Alkodsi, A Pasanen… - Blood, The Journal …, 2022 - ashpublications.org
Inadequate molecular and clinical stratification of the patients with high-risk diffuse large B-
cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalized …
cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalized …
[HTML][HTML] Positron emission tomography–directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials …
PURPOSE Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in
25% to 30% of patients, with better overall survival (OS) than that for advanced-stage …
25% to 30% of patients, with better overall survival (OS) than that for advanced-stage …
Mendelian randomization as a tool to gain insights into the mosaic causes of autoimmune diseases
C Chen, P Wang, RD Zhang, Y Fang, LQ Jiang… - Autoimmunity …, 2022 - Elsevier
Autoimmune diseases (ADs) are a broad range of disorders which are characterized by long-
term inflammation and tissue damage arising from an immune response against one's own …
term inflammation and tissue damage arising from an immune response against one's own …
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA
S Le Gouill, H Ghesquieres, L Obéric… - Blood, The Journal …, 2021 - ashpublications.org
Rituximab plus polychemotherapy is the standard of care in diffuse large B-cell lymphoma
(DLBCL). GAINED, a randomized phase 3 trial, compared obinutuzumab to rituximab …
(DLBCL). GAINED, a randomized phase 3 trial, compared obinutuzumab to rituximab …
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients
JJ Eertink, CN Burggraaff, MW Heymans… - Blood …, 2021 - ashpublications.org
Interim 18F-fluorodeoxyglucose positron emission tomography (Interim-18F-FDG-PET,
hereafter I-PET) has the potential to guide treatment of patients with diffuse large B-cell …
hereafter I-PET) has the potential to guide treatment of patients with diffuse large B-cell …
COVID‐19 in patients receiving CD20‐depleting immunochemotherapy for B‐cell lymphoma
E Gaitzsch, V Passerini, E Khatamzas, CD Strobl… - …, 2021 - Wiley Online Library
The clinical and immunological impact of B‐cell depletion in the context of coronavirus
disease 2019 (COVID‐19) is unclear. We conducted a prospectively planned analysis of …
disease 2019 (COVID‐19) is unclear. We conducted a prospectively planned analysis of …
Defining and treating high-grade B-cell lymphoma, NOS
High-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), is a recently introduced
diagnostic category for aggressive B-cell lymphomas. It includes tumors with Burkitt-like or …
diagnostic category for aggressive B-cell lymphomas. It includes tumors with Burkitt-like or …
Limited-stage diffuse large B-cell lymphoma
EA Hawkes, A Barraclough… - Blood, The Journal of the …, 2022 - ashpublications.org
Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype, is localized
in 25% to 30% of patients. Prognosis in patients with limited-stage DLBCL (LS-DLBCL) is …
in 25% to 30% of patients. Prognosis in patients with limited-stage DLBCL (LS-DLBCL) is …